Advertisement
Advertisement
MRKR
Marker Therapeutics, Inc. Common Stock
0.89
USDSponsored
0.00
-0.30%
Nov 06, 15:59 UTC -5
Closed
After-Market
0.90
+0.01
+0.81%
Marker Therapeutics, Inc. Common Stock (MRKR) Earnings
MRKR Earnings Reports
Positive Surprise Ratio
MRKR beat 21 of 29 last estimates.
72%
Next Report
Next Week
Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
$2.16M
/-$0.11
Implied change from Q2 26 (Revenue/ EPS)
+216.83%
/+22.22%
Implied change from Q3 25 (Revenue/ EPS)
+74.99%
/-8.33%
Marker Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 14, 2026, MRKR reported earnings of -0.09 USD per share (EPS) for Q2 26, beating the estimate of -0.22 USD, resulting in a 59.28% surprise. Revenue reached 681.00 thousand, compared to an expected 695.64 thousand, with a -2.10% difference. The market reacted with a +1.75% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.11 USD, with revenue projected to reach 2.16 million USD, implying an increase of 22.22% EPS, and increase of 216.83% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Guardian Pharmacy Services, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.30
Actual
$0.33
Surprise
+7.84%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.02
Actual
$0.06
Surprise
+144.90%
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.89
Actual
$1.96
Surprise
+3.17%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.32
Actual
$0.36
Surprise
+9.16%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.36
Surprise
-11.15%
Profound Medical Corp. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.18
Actual
-$0.21
Surprise
-11.41%
Akebia Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.03
Actual
-$0.04
Surprise
-6.95%
FAQ
What were Marker Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Marker Therapeutics, Inc. Common Stock reported EPS of -$0.09, beating estimates by 59.28%, and revenue of $681.00K, -2.1% below expectations.
How did the market react to Marker Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 1.75%, changed from $1.14 before the earnings release to $1.16 the day after.
When is Marker Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for Marker Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Marker Therapeutics, Inc. Common Stock is expected to report EPS of -$0.11 and revenue of $2.16M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.